en · de · es · fr · pt
cjc-1295-notes.peptides9002.com › Info › Background And Receptor Mechanism — Common Mistakes

Background And Receptor Mechanism — Common Mistakes

By Editorial Desk · published 2025-11-10 · last reviewed 2025-12-08 · Info

lyophilization raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.

Reviewed 2025-12-08. Anything still debated is marked as such rather than presented as settled.

Background and Receptor Mechanism

Two principal forms appear in the literature and in research supply. One carries a drug affinity complex, a maleimide-based group that forms a covalent bond with circulating albumin. This linkage slows clearance and produces a long-lasting elevation of peptide levels. The other form lacks that group and is often labeled MOD GRF(1-29). It has a much shorter circulation time. Both variants retain the same core receptor-binding sequence. Reported half-lives differ substantially between the two.

At the pituitary, the peptide binds the growth hormone-releasing hormone receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone. Somatostatin and other hypothalamic signals modulate this response. Negative feedback from insulin-like growth factor 1 also influences output. The same regulatory architecture operates with the native hormone. Whether the synthetic analog alters feedback dynamics over repeated exposure remains an open question. Most published receptor work uses cell models rather than intact human systems.

Background and Molecular Features

CJC-1295 is a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. Its sequence corresponds to the first twenty-nine residues of human GHRH, with four substitutions that slow enzymatic breakdown. Early descriptions placed the compound in research on growth hormone deficiency and related conditions, and later literature groups it with the long-acting GHRH analogs. The name appears in both laboratory and popular fitness writing, where it sometimes labels chemically different peptides.

Two related peptides circulate under the CJC-1295 label, and they differ mainly in how long they persist in circulation. The version carrying a drug affinity complex includes a maleimidopropionic acid linker that forms a covalent bond with serum albumin. The other version, usually written as modified GRF(1-29) or tetrasubstituted GRF(1-29), lacks that linker and is cleared quickly. Mixing the two produces inconsistent readings of published half-life values, because the linker rather than the receptor-facing sequence drives most of the difference.

The core sequence keeps the receptor-binding region of GHRH while replacing four positions that are vulnerable to dipeptidyl peptidase-4 and other proteases. Substitutions at positions 2, 8, 15, and 27 raise metabolic stability relative to the natural hormone. The N-terminal residues remain essential for activity, so changes there generally lower potency. Molecular weight sits near 3368 daltons for the tetrasubstituted analog without the linker, while the albumin-binding form is heavier because of the added maleimide group.

Cjc-1295 at a glance

PropertyValueNotes
Molecular weight, DAC formAbout 3647 DaVaries with salt form
Molecular weight, non-DAC formAbout 3358 DaMOD GRF(1-29)
Solubility classWater solubleAlso dissolves in polar solvents
Reported half-life, DAC formAbout five to eight daysValues from human studies
Common synonymsCJC-1295; MOD GRF(1-29)Name depends on variant

Structure And Receptor Pharmacology

CJC-1295 belongs to a class of synthetic peptides modeled on growth hormone releasing hormone, a forty-four amino acid signal produced by the hypothalamus. The compound is built from the first twenty-nine residues of the natural sequence, with four substitutions introduced at positions 2, 8, 15 and 27. These changes were designed to slow enzymatic breakdown while preserving receptor activation. The result is a peptide that is shorter than native GHRH and considerably more resistant to ordinary clearance pathways in circulation.

Two related forms appear under the CJC-1295 name. The simpler analogue, commonly written as modified GRF(1-29), carries the four substitutions but no additional conjugation. The second form attaches a maleimidopropionic acid linker to a lysine residue, a modification frequently called the drug affinity complex. That linker reacts with the free thiol on serum albumin to form a covalent bond. Because albumin has a long residence time in blood, the conjugated peptide stays in circulation far longer than the unconjugated analogue.

Receptor level activity follows the canonical GHRH pathway. The peptide binds the GHRH receptor, a class B G protein coupled receptor on somatotroph cells of the anterior pituitary. Binding raises intracellular cyclic AMP, which promotes calcium entry and the release of growth hormone into the bloodstream. Because the molecule acts at the same receptor as the endogenous hormone, its effect is superimposed on the natural pulsatile rhythm rather than replacing it. Whether sustained receptor occupation leads to desensitization is not fully settled.

Related pages on this site

Analytical Characterization and Storage

Stability depends heavily on physical state. A lyophilized powder kept dry, desiccated, and shielded from light typically holds its integrity for months to years at minus twenty degrees Celsius, and longer at minus eighty. Once dissolved, the peptide becomes far more vulnerable, since peptide bond hydrolysis, oxidation of susceptible residues, and aggregation all proceed faster in solution. Buffers near neutral pH are generally gentler than strongly acidic or alkaline conditions. Repeated freeze-thaw cycles and exposure to air-liquid interfaces during vigorous mixing cause losses that are easy to overlook.

Verification matters because research peptides vary widely in quality. A certificate of analysis is only as reliable as the method behind it, and a single chromatographic trace reveals little about counter-ions, residual solvents, or water content. Independent laboratories commonly pair mass confirmation with chromatographic purity and, where relevant, quantify water along with acetate or trifluoroacetate content. Reported purity figures are not standardized across suppliers, so a stated value such as ninety-eight percent is not directly comparable unless the analytical method, column, and detection wavelength accompany it.

Notes from published material

A typical Indian meal is built on a plain cereal, complemented by savoury dishes. The cooked cereal could be steamed rice; chapati, a thin unleavened bread; idli, a steamed breakfast cake; or dosa, a griddled pancake. The savoury dishes might include lentils, pulses, vegetables, meat, poultry and fish commonly spiced with ginger and garlic, but also coriander, cumin, turmeric, cinnamon, cardamom and others. In some instances, the ingredients may be mixed during the cooking process. India has distinctive vegetarian cuisines, each a feature of the geographical and cultural histories of its communities. About 20% to 39% of India's population consists of vegetarians. Although meat is eaten widely, the proportional consumption of meat is low. The most significant import of cooking techniques into India during the last millennium occurred during the Mughal Empire, spreading into northern India from regions to its northwest, along with dishes such as pilaf. Onions, garlic, almonds, and spices were added to the simple yogurt marinade of Persia. Rice was partially cooked and layered alternately with sauteed meat, the pot sealed tightly, and slow cooked according to another Persian cooking technique, to produce biryani, a feature of festive dining in many parts of India. The diversity of Indian food served worldwide has been partially concealed by the dominance of Punjabi cuisine.

Because of its spread with humans worldwide, there has been some uncertainty about its exact original, native range, although it has been recognized as being likely in the subtropical parts of the Afro-Eurasia, thus with a preference for warmer climates, and recent authorities regards it as only native to Asia. As a synanthropic species, Pholcus phalangioides has largely had its modern geographic distribution determined by the spread of humans around the world. Today, these spiders can be found in most of the temperate countries of every continent in the world. P. phalangioides are not suited for survival in cold environments, which is why they prefer the warmth of the indoors when in these regions, specifically inside human dwellings. These spiders have a particular affinity for dimly lit, dark areas that are quiet and calm. They are commonly found in the corners of buildings and people's homes as well as in attics. Populations of Pholcus phalangioides living outdoors can be found in caves and in between rock crevices.

== IUBMB classification == Oxidoreductases, enzymes that catalyze oxidation-reduction reactions, constitute Class EC 1 of the IUBMB classification of enzyme-catalyzed reactions. Any of these may be called dehydrogenases, especially those in which NAD+ is the electron acceptor (oxidant), but reductase is also used when the physiological emphasis on reduction of the substrate, and oxidase is used only when O2 is the electron acceptor. The systematic name of an oxidoreductase is "donor:acceptor oxidoreductase", but, when possible, it is more conveniently named as "donor dehydrogenase".

Sources: en.wikipedia.org

Background from the literature

=== Legal status === On 16 December 2021, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Ontilyv, intended for the treatment of Parkinson's disease. The applicant for this medicinal product is Bial Portela & Companhia S.A. Opicapone was approved for medical use in the European Union in February 2022.

==== Medical and research uses ==== Radium (usually in the form of radium chloride or radium bromide) was used in medicine to produce radon gas, which in turn was used as a cancer treatment. Several of these radon sources were used in Canada in the 1920s and 1930s. However, many treatments that were used in the early 1900s are not used anymore because of the harmful effects radium bromide exposure caused. Some examples of these effects are anaemia, cancer, and genetic mutations. As of 2011, safer gamma emitters such as 60Co, which is less costly and available in larger quantities, are usually used to replace the historical use of radium in this application, but factors including increasing costs of cobalt and risks of keeping radioactive sources on site have led to an increase in the use of linear particle accelerators for the same applications. In the U.S., from 1940 through the 1960s, radium was used in nasopharyngeal radium irradiation, a treatment that was administered to children to treat hearing loss and chronic otitis. The procedure was also administered to airmen and submarine crew to treat barotrauma. Early in the 1900s, biologists used radium to induce mutations and study genetics. As early as 1904, Daniel MacDougal used radium in an attempt to determine whether it could provoke sudden large mutations and cause major evolutionary shifts. Thomas Hunt Morgan used radium to induce changes resulting in white-eyed fruit flies.

Transferrin receptor 2 (TfR2) is a protein that in humans is encoded by the TFR2 gene. This protein is involved in the uptake of transferrin-bound iron into cells by endocytosis, although its role is minor compared to transferrin receptor 1.

Sources: en.wikipedia.org

Frequently asked questions

What is CJC-1295?

It is a synthetic peptide modeled on growth hormone-releasing hormone. The molecule is used in research on pituitary growth hormone secretion. It differs from the natural hormone through several stabilizing substitutions.

How do the DAC and non-DAC forms differ?

The DAC form carries a maleimide group that binds albumin and extends circulation time. The non-DAC form lacks this group and clears much faster. Both share the same receptor-binding core.

What receptor does it act on?

It targets the growth hormone-releasing hormone receptor on pituitary somatotroph cells. Activation raises cyclic AMP and promotes growth hormone release. Normal feedback pathways remain part of the response.

What is the difference between CJC-1295 and natural GHRH?

Natural GHRH is degraded quickly by dipeptidyl peptidase-4 and related enzymes, giving it a half-life measured in minutes. CJC-1295 carries substitutions that slow that breakdown, so it stays intact longer. Both act at the same pituitary receptor and produce the same class of signal.

Network